PDS Biotechnology Corporation announced the reopening of recruitment in the National Cancer Institute-led Phase II clinical trial evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV cancers.
[PDS Biotechnology Corporation]
6445212
nan
items
1
apa
0
default
asc
1
169781
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
